Australia's Sirtex Medical has been on a rollercoaster reflected in its share price as a biotech that alternately has seen brokers target above AUS $50/share earlier this year. But after the company reported disappointing results of its Sirflox colorectal cancer treatment in trials in mid-March, shares are now around AUS $21 because Sirflox didn't achieve the primary endpoint of improved cancer survival rates. Still, a secondary study showed positive signs that Sirflox helped treat liver tumors. This has kept interest strong because no previous randomized clinical trial has examined liver metastases of colorectal cancer in such detail. Another one to watch from Down Under. Sirtex's website